Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL21879029 | 0.80 | ALDH1A1 (0.57) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL11489570 | 0.80 | ALDH1A1 (0.57) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL5712062 | 0.80 | ALDH1A1 (0.57) | ALDH1A1TSHR | |
| Cyclopentane SCHEMBL29088065 | 0.80 | — | — | |
| Cyclohexane SCHEMBL12475806 | 0.80 | ALDH1A1 (0.57) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL12476090 | 0.80 | ALDH1A1 (0.57) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL185456 | 0.80 | — | — | |
| Cyclohexane SCHEMBL12475625 | 0.80 | ALDH1A1 (0.57) | ALDH1A1TSHR | |
| 1,2-Dichloroethane SCHEMBL5324114 | 0.79 | — | — | |
| 1,2-Dichloroethane SCHEMBL127 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| CN-108568128-B | Method for recovering synthetic solvent | 东丽株式会社 | 2021-09-24 | — | — | CN | disclosed |
| CN-106459084-B | Macrocyclic compound | 拜耳医药股份有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-108368129-A | New modification macrocyclic compound | 拜耳医药股份有限公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-108290903-A | New big ring sulphonyl diimine compounds | 拜耳医药股份有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-106459084-A | Novel macrocyclic compounds | 拜耳医药股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2011004384-A2 | PROCESS FOR THE PREPARATION OF EPROSARTAN | GLOCHEM INDUSTRIES LIMITED (IN) | 2011-01-13 | — | — | WO | disclosed |
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-09-03 | — | — | US | disclosed |
| EP-1817284-A4 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1817302-A4 | PIPERIDINYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1817285-A2 | CYCLOALKYL KETO PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1817284-A2 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007081897-A2 | FUSED TRIAZOLE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2006073589-A2 | CYCLOALKYL KETO PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006057977-A2 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006057921-A2 | PIPERIDINYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-5681961-A | TREATMENT AND/OR PREVENTION OF THROMBOEMBOLIC DISORDERS, ARTERIOSCLEROSIS, METASTASIS. ISCHEMIA, ASTHMA, ALLERGIES | DR. KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| US-5426119-A | Thromboxane antagonists | DR. KARL THOMAE GMBH (DE) | 1995-06-20 | — | — | US | disclosed |
| US-5294626-A | Thromboxane synthesis inhibitors and anticoagulants | DR. KARL THOMAS GMBH (DE) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | ALDH1A1 61/4885TSHR 3654/4885TDP1 2098/4885 |
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | ALDH1A1 1396/4885TSHR 546/4885TDP1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.